Literature DB >> 33062117

Descriptive epidemiology of Lassa fever in Nigeria, 2012-2017.

Onyebuchi Augustine Okoro1, Eniola Bamgboye2, Chioma Dan-Nwafor3, Chukwuma Umeokonkwo4, Elsie Ilori3, Rimamdeyati Yashe3, Muhammad Balogun5, Patrick Nguku5, Chikwe Ihekweazu3.   

Abstract

INTRODUCTION: Lassa fever, an acute viral hemorrhagic zoonotic disease is endemic in some parts of Nigeria. The disease alert and outbreak threshold are known; however, there has been a shift from the previous seasonal transmission pattern to an all year-round transmission. We described data on Lassa fever and highlighted the magnitude of the disease over a six-year period.
METHODS: we conducted a secondary data analyses of Lassa fever specific surveillance data from the Integrated Disease Surveillance and Response (IDSR) records of all states in Nigeria over a six-year period (2012-2017).
RESULTS: a total of 5974 suspected cases were reported within the study period; of these, 759 (12.7%) were confirmed by laboratory diagnosis. Highest number of cases was recorded in 2012. Edo and Ondo states in the southern region of the country were mostly affected within the study period. The seasonal trend of Lassa fever cases showed peaks within January to March, except for year 2015.
CONCLUSION: there was a high burden of Lassa fever in Nigeria especially in the southern part. Lassa fever transmission occurs all year-round with peaks in January and March. There is need to develop preparedness plans and define thresholds for Lassa fever epidemic. Copyright: Onyebuchi Augustine Okoro et al.

Entities:  

Keywords:  Lassa fever; Nigeria; outbreak

Mesh:

Year:  2020        PMID: 33062117      PMCID: PMC7532845          DOI: 10.11604/pamj.2020.37.15.21160

Source DB:  PubMed          Journal:  Pan Afr Med J


  16 in total

Review 1.  Lassa fever: epidemiology, clinical features, and social consequences.

Authors:  J Kay Richmond; Deborah J Baglole
Journal:  BMJ       Date:  2003-11-29

2.  Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations.

Authors:  D G Bausch; A H Demby; M Coulibaly; J Kanu; A Goba; A Bah; N Condé; H L Wurtzel; K F Cavallaro; E Lloyd; F B Baldet; S D Cissé; D Fofona; I K Savané; R T Tolno; B Mahy; K D Wagoner; T G Ksiazek; C J Peters; P E Rollin
Journal:  Vector Borne Zoonotic Dis       Date:  2001       Impact factor: 2.133

Review 3.  Lassa fever in West African sub-region: an overview.

Authors:  O Ogbu; E Ajuluchukwu; C J Uneke
Journal:  J Vector Borne Dis       Date:  2007-03       Impact factor: 1.688

Review 4.  Lassa virus infection in Nigeria: clinical perspective overview.

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2010-12       Impact factor: 1.798

5.  Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.

Authors:  J D Frame; J M Baldwin; D J Gocke; J M Troup
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

6.  Prevalence of Lassa virus among rodents trapped in three South-South States of Nigeria.

Authors:  D E Agbonlahor; A Erah; I M Agba; F E Oviasogie; A F Ehiaghe; M Wankasi; O A Eremwanarue; I J Ehiaghe; E C Ogbu; R I Iyen; S Abbey; M Y Tatfeng; J Uhunmwangho
Journal:  J Vector Borne Dis       Date:  2017 Apr-Jun       Impact factor: 1.688

7.  A serological survey of Lassa fever in Liberia.

Authors:  A Bloch
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

8.  Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012).

Authors:  Nnennaya A Ajayi; Chinedu G Nwigwe; Ben N Azuogu; Benson N Onyire; Elizabeth U Nwonwu; Lawrence U Ogbonnaya; Francis I Onwe; Tobin Ekaete; Stephan Günther; Kingsley N Ukwaja
Journal:  Int J Infect Dis       Date:  2013-07-17       Impact factor: 3.623

9.  A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018.

Authors:  Chioma C Dan-Nwafor; Oladipupo Ipadeola; Elizabeth Smout; Elsie Ilori; Ayodele Adeyemo; Chukwuma Umeokonkwo; Damian Nwidi; Williams Nwachukwu; Winifred Ukponu; Emeka Omabe; Uchenna Anaebonam; Nneka Igwenyi; Gordon Igbodo; Womi Eteng; Ikemefule Uzoma; Muhammed Saleh; Joseph Agboeze; Samuel Mutbam; Tanyth de Gooyer; Rosie Short; Everistus Aniaku; Robinson Onoh; Emeka Ogah; Patrick Nguku; John Oladejo; Clement Peter; Olubunmi Ojo; Chikwe Ihekweazu
Journal:  Int J Infect Dis       Date:  2019-03-28       Impact factor: 3.623

10.  Increase in Lassa Fever Cases in Nigeria, January-March 2018.

Authors:  Elsie A Ilori; Christina Frank; Chioma C Dan-Nwafor; Oladipupo Ipadeola; Amrei Krings; Winifred Ukponu; Oboma E Womi-Eteng; Ayodele Adeyemo; Samuel K Mutbam; Emmanuel O Musa; Clement L P Lasuba; Wondimagegnehu Alemu; Sylvanus Okogbenin; Ephraim Ogbaini; Uche Unigwe; Emeka Ogah; Robinson Onoh; Chukwuyem Abejegah; Olufemi Ayodeji; Chikwe Ihekweazu
Journal:  Emerg Infect Dis       Date:  2019-05-17       Impact factor: 6.883

View more
  2 in total

Review 1.  The deuce-ace of Lassa Fever, Ebola virus disease and COVID-19 simultaneous infections and epidemics in West Africa: clinical and public health implications.

Authors:  Nnabueze Darlington Nnaji; Helen Onyeaka; Rine Christopher Reuben; Olivier Uwishema; Chinasa Valerie Olovo; Amarachukwu Anyogu
Journal:  Trop Med Health       Date:  2021-12-30

2.  Epidemiological description of and response to a large yellow fever outbreak in Edo state Nigeria, September 2018 - January 2019.

Authors:  E Nwachukwu William; John Oladejo; Chinenye Mary Ofoegbunam; Chimezie Anueyiagu; Festus Dogunro; Sandra Okwudili Etiki; Botson Iliya Dachung; Celestina Obiekea; Bukola Aderoju; Kayode Akanbi; Idayat Temitope Adeyemi; Gboyega Adekunle Famokun; Obi Emelife; Irowa Williams Osamwonyi; Chinwe Lucia Ochu; Alice Abiode; Faith Ireye; Martins Chukwuji; Oladipupo Ipadeola; Musa Saiki; Ifeanyi Okudo; Dorathy Nwodo; Joseph Avuwa Oteri; Elsie Ilori; Nwando Mba; Chikwe Ihekweazu
Journal:  BMC Public Health       Date:  2022-08-30       Impact factor: 4.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.